{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T02:12:13Z","timestamp":1693966333094},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[1994,12,1]],"date-time":"1994-12-01T00:00:00Z","timestamp":786240000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharm World Sci"],"published-print":{"date-parts":[[1994,12]]},"DOI":"10.1007\/bf02178563","type":"journal-article","created":{"date-parts":[[2005,10,6]],"date-time":"2005-10-06T10:31:42Z","timestamp":1128594702000},"page":"334-342","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacotherapy of congestive heart failure"],"prefix":"10.1007","volume":"16","author":[{"given":"P. A.","family":"Zwieten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF02178563_CR1","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0735-1097(92)90167-L","volume":"20","author":"M Packer","year":"1992","unstructured":"Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure.) J Am Coll Cardiol 1992;20:248\u201354.","journal-title":"J Am Coll Cardiol"},{"key":"BF02178563_CR2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0140-6736(92)90405-R","volume":"340","author":"M Packer","year":"1992","unstructured":"Packer M. Pathophysiology of chronic heart failure. Lancet 1992;340:88\u201391.","journal-title":"Lancet"},{"key":"BF02178563_CR3","doi-asserted-by":"crossref","first-page":"3C","DOI":"10.1016\/0002-9149(93)90081-M","volume":"71","author":"M Packer","year":"1993","unstructured":"Packer M. How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease. Am J Cardiol 1993;71:3C-11C.","journal-title":"Am J Cardiol"},{"key":"BF02178563_CR4","first-page":"311","volume":"1","author":"PA Zwieten van","year":"1994","unstructured":"van Zwieten PA, Lie Kl. Neuro-endocrine compensatory mechanisms as a target for the drug treatment of congestive heart failure. Cardiologie 1994;1:311\u201320.","journal-title":"Cardiologie"},{"key":"BF02178563_CR5","first-page":"1208","volume":"138","author":"PA Zwieten van","year":"1994","unstructured":"van Zwieten PA, Lie Kl. Neuro-humorale compensatieprocessen bij chronische decompensatio cordis. De invloed van geneesmiddelen [Neuro-humoral compensation phenomena in chronic congestive heart failure. The influence of drugs]. Ned Tijdschr Geneeskd 1994;138:1208\u201313.","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"suppl C","key":"BF02178563_CR6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/eurheartj\/12.suppl_C.14","volume":"12","author":"E Ritz","year":"1991","unstructured":"Ritz E, Fliser D. The kidney in congestive heart failure. Eur Heart J 1991;12 suppl C:14\u201320.","journal-title":"Eur Heart J"},{"key":"BF02178563_CR7","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/0140-6736(92)90406-S","volume":"340","author":"M Packer","year":"1992","unstructured":"Packer M. Treatment of chronic heart failure. Lancet 1992; 340:92\u20135.","journal-title":"Lancet"},{"key":"BF02178563_CR8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/hrt.72.2_Suppl.S51","volume":"72","author":"PA Zwieten van","year":"1994","unstructured":"van Zwieten PA. Neuro-endocrine effects of diuretics in heart failure. Br Heart J 1994;72:51\u20133.","journal-title":"Br Heart J"},{"key":"BF02178563_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-103-1-1","volume":"103","author":"GS Francis","year":"1985","unstructured":"Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neuro-humoral axis. Ann Intern Med 1985;103:1\u20136.","journal-title":"Ann Intern Med"},{"key":"BF02178563_CR10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/hrt.57.1.17","volume":"57","author":"J Bayliss","year":"1987","unstructured":"Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuro-endocrine effects of introducing diuretics. Br Heart J 1987;57:17\u201322.","journal-title":"Br Heart J"},{"key":"BF02178563_CR11","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/0002-9149(89)90588-2","volume":"64","author":"SR Goldsmith","year":"1989","unstructured":"Goldsmith SR, Francis G, Cohn JN. Attenuation of the pressor response to intravenous furosemide by angiotensin converting enzyme inhibition in congestive heart failure. Am J Cardiol 1989;64:1382\u20135.","journal-title":"Am J Cardiol"},{"key":"BF02178563_CR12","doi-asserted-by":"crossref","first-page":"426","DOI":"10.2165\/00003495-198428050-00003","volume":"28","author":"A Ward","year":"1984","unstructured":"Ward A, Heel RC. Bumetanide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs 1984;28:426\u201364.","journal-title":"Drugs"},{"key":"BF02178563_CR13","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2165\/00003495-198529060-00002","volume":"29","author":"SP Clissold","year":"1985","unstructured":"Clissold SP, Brogden RN. Piretanide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1985;29:489\u2013530.","journal-title":"Drugs"},{"issue":"Suppl 3","key":"BF02178563_CR14","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2165\/00003495-199100413-00004","volume":"41","author":"DC Brater","year":"1991","unstructured":"Brater DC. Clinical pharmacology of loop diuretics. Drugs 1991;41 Suppl 3:14\u201322.","journal-title":"Drugs"},{"key":"BF02178563_CR15","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJM198903163201101","volume":"320","author":"R Bianco Di","year":"1989","unstructured":"Di Bianco R, Shabetai R, Kossuk W, Moran J, Schlant RC, Wright R. A comparison of oral milrinone, digoxin and their combination in the treatment of patients with chronic heart failure. N Engl J Med 1989;320:677\u201383.","journal-title":"N Engl J Med"},{"key":"BF02178563_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199307013290101","volume":"329","author":"M Packer","year":"1993","unstructured":"Packer M, Gheorgiade M, Young JB, Constantini PJ, Adams KF, Cody RJ, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-convertingenzyme inhibitors. N Engl J Med 1993;329:1\u20137.","journal-title":"N Engl J Med"},{"key":"BF02178563_CR17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1161\/01.CIR.80.1.65","volume":"80","author":"DW Ferguson","year":"1989","unstructured":"Ferguson DW, Berg WJ, Sanders JS, Roach PJ, Kempf JS, Kienzle MG. Sympatho-inhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings. Circulation 1989;80:65\u201377.","journal-title":"Circulation"},{"issue":"Suppl VII","key":"BF02178563_CR18","first-page":"VII68","volume":"87","author":"DW Ferguson","year":"1993","unstructured":"Ferguson DW. Sympathetic mechanisms in heart failure. Patho-physiological and pharmacological implications. Circulation 1993;87 Suppl VII:VII68\u201375.","journal-title":"Circulation"},{"key":"BF02178563_CR19","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/0735-1097(93)90579-P","volume":"22","author":"DJ Veldhuisen van","year":"1993","unstructured":"van Veldhuisen DJ, Manin 't Veld AJ, Dunselman PHJM, Lok DJA, Dohmen HJM, Poortermans JC, et al. Double blind, placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure. Results of the Dutch Ibopamine Multicentre Trial (DIMT). J Am Coll Cardiol 1993;22:1564\u201373.","journal-title":"J Am Coll Cardiol"},{"issue":"suppl H","key":"BF02178563_CR20","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/eurheartj\/9.suppl_H.85","volume":"9","author":"PA Zwieten van","year":"1988","unstructured":"van Zwieten PA. Receptor-mediated inotropic drugs. Eur Heart J 1988;9 suppl H:85\u201390.","journal-title":"Eur Heart J"},{"key":"BF02178563_CR21","first-page":"2281","volume":"47","author":"PA Zwieten van","year":"1990","unstructured":"van Zwieten PA. Dopamine en dopaminerge farmaca als therapeutica bij decompensatio cordis [Dopamine and dopaminergic agents as therapeutics in congestive heart failure]. Ned Tijdschr Geneeskd 1990;47:2281\u20134.","journal-title":"Ned Tijdschr Geneeskd"},{"key":"BF02178563_CR22","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJM199111213252103","volume":"325","author":"M Packer","year":"1991","unstructured":"Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, et al.; for the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468\u201375.","journal-title":"N Engl J Med"},{"key":"BF02178563_CR23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/00003495-199243010-00003","volume":"43","author":"LW Stevenson","year":"1992","unstructured":"Stevenson LW, Fonarow G. Vasodilators. A re-evaluation of their role in heart failure. Drugs 1992;43:15\u20136.","journal-title":"Drugs"},{"issue":"Suppl 4","key":"BF02178563_CR24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00003495-199400474-00008","volume":"47","author":"JN Cohn","year":"1994","unstructured":"Cohn JN. Vasodilators in heart failure. Conclusions from VHEFT II and rationale for V-HEFT III. Drugs 1994; 47 Suppl 4:47\u201358.","journal-title":"Drugs"},{"issue":"Suppl VI","key":"BF02178563_CR25","first-page":"40","volume":"87","author":"GS Francis","year":"1993","unstructured":"Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A. Plasma norepinephrine, plasma renin activity and congestive heart failure: relations to survival and the effects of therapy in V-HEFT II. Circulation 1993;87 Suppl VI:40\u20138.","journal-title":"Circulation"},{"key":"BF02178563_CR26","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/hrt.54.4.405","volume":"54","author":"BP McGrath","year":"1985","unstructured":"McGrath BP, Arnolda L, Matthews PG, Jackson B, Jennings G, Kiat H, et al. Controlled trial of enalapril in congestive heart failure. Br Heart J 1985;54:405\u201314.","journal-title":"Br Heart J"},{"key":"BF02178563_CR27","first-page":"102","volume":"3","author":"Enalapril Congestive Heart Failure Investigators","year":"1987","unstructured":"Enalapril Congestive Heart Failure Investigators. Long-term effects of enalapril in patients with congestive heart failure: a multicenter, placebo-controlled trial. Heart Failure 1987;3: 102\u20137.","journal-title":"Heart Failure"},{"issue":"Suppl 2","key":"BF02178563_CR28","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/00005344-199000152-00008","volume":"15","author":"GAJ Riegger","year":"1990","unstructured":"Riegger GAJ. The effects of ACE-inhibitors in the treatment of congestive heart failure. J Cardiovasc Pharmacol 1990; 15 Suppl 2:41\u20136.","journal-title":"J Cardiovasc Pharmacol"},{"key":"BF02178563_CR29","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","volume":"327","author":"SOLVD investigators","year":"1992","unstructured":"SOLVD investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685\u201391.","journal-title":"N Engl J Med"},{"key":"BF02178563_CR30","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJM199209033271010","volume":"327","author":"JN Cohn","year":"1992","unstructured":"Cohn JN. The prevention of heart failure \u2014 a new agenda. N Engl J Med 1992;327:725\u20137.","journal-title":"N Engl J Med"},{"key":"BF02178563_CR31","first-page":"284","volume-title":"Het Medisch Jaar 1993","author":"PA Zwieten van","year":"1993","unstructured":"van Zwieten PA. Inodilatoren: inotrope\/vaatverwijdende farmaca met een dopaminerge component [Inodilator drugs: inotropic\/vasodilator drugs with a dopaminergic component]. In: Het Medisch Jaar 1993. Houten: Bohn Stafleu van Loghum, 1993:284\u201392."},{"key":"BF02178563_CR32","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1476-5381.1992.tb12742.x","volume":"107","author":"LJ Woerkens van","year":"1992","unstructured":"van Woerkens LJ, Boomsma F, Man in 't Veld AJ, Bevers MM, Verdouw PD. Differential cardiovascular and neuro-endocrine effects of epinine and dopamine in conscious pigs before and after adrenoceptor blockade. Br J Pharmacol 1992; 107:303\u201310.","journal-title":"Br J Pharmacol"},{"key":"BF02178563_CR33","first-page":"439","volume":"257","author":"G Bravo","year":"1991","unstructured":"Bravo G, Ghysel-Burton J, Jaumin P, Godfraind T. A comparison of the inotropic effects of dopamine and epinine in human isolated cardiac preparations. J Pharmacol Exp Ther 1991;257:439\u201343.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF02178563_CR34","first-page":"20","volume-title":"Ibopamine in heart failure. Efficacy and safety in clinical and experimental studies [dissertation]","author":"DJ Veldhuisen van","year":"1993","unstructured":"van Veldhuisen DJ. Ibopamine in heart failure. Efficacy and safety in clinical and experimental studies [dissertation]. Groningen: Rijksuniversiteit Groningen, 1993:20\u20139, 116\u201340."},{"key":"BF02178563_CR35","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/0002-9149(91)90193-O","volume":"68","author":"DJ Veldhuisen van","year":"1991","unstructured":"van Veldhuisen DJ, Crijns Hj, Girbes ARJ, Tob\u00e9 JM, Wiesfeld ACP, Lie Kl. Electro-physiologic profile of ibopamine in patients with congestive heart failure and ventricular tachycardia and relation to its effects on hemodynamics and plasma catecholamines. Am J Cardiol 1991;68:1194\u2013202.","journal-title":"Am J Cardiol"},{"key":"BF02178563_CR36","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/eurheartj\/14.2.279","volume":"14","author":"ARJ Girbes","year":"1993","unstructured":"Girbes ARJ, Kalisvaart CJ, van Veldhuisen DJ, Smit AJ, Pasteuning WH. Effects of ibopamine on renal haemodynamics in patients with severe congestive heart failure. Eur Heart J 1993;14:279\u201383.","journal-title":"Eur Heart J"},{"key":"BF02178563_CR37","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/0002-9149(92)90203-B","volume":"70","author":"Cas L Dei","year":"1992","unstructured":"Dei Cas L, Metra M, Visioli O. Effects of acute and chronic ibopamine administration on resting and exercise hemodynamics, plasma catecholamines and functional capacity of patients with chronic congestive heart failure. Am J Cardiol 1992;70:629\u201334.","journal-title":"Am J Cardiol"},{"key":"BF02178563_CR38","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","volume":"316","author":"CONSENSUS Trial Group","year":"1987","unstructured":"CONSENSUS Trial Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987;316: 1429\u201335.","journal-title":"N Engl J Med"},{"key":"BF02178563_CR39","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"SOLVD-investigators","year":"1991","unstructured":"SOLVD-investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293\u2013302.","journal-title":"N Engl J Med"},{"key":"BF02178563_CR40","first-page":"169","volume-title":"Congestive cardiac failure","author":"P Held","year":"1993","unstructured":"Held P, Swedberg K. ACE-inhibitors in the treatment of heart failure. In: Barnett DB, editor. Congestive cardiac failure. New York: Dekker, 1993:169\u201383."},{"key":"BF02178563_CR41","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJM198606123142404","volume":"314","author":"JN Cohn","year":"1986","unstructured":"Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study (V-HEFT). N Engl J Med 1986;314:1547\u201352.","journal-title":"N Engl J Med"},{"key":"BF02178563_CR42","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJM199108013250502","volume":"325","author":"JN Cohn","year":"1991","unstructured":"Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of congestive heart failure. N Engl J Med 1991;325:303\u201310.","journal-title":"N Engl J Med"},{"key":"BF02178563_CR43","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1161\/01.CIR.79.3.483","volume":"79","author":"SM Heilbrunn","year":"1989","unstructured":"Heilbrunn SM, Shali P, Bristow MR, Valentine HA, Mullin AV, Ginsberg R, et al. Increased \u0392-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation 1989;79:483\u201390.","journal-title":"Circulation"},{"issue":"Suppl 1","key":"BF02178563_CR44","first-page":"177","volume":"82","author":"M Packer","year":"1990","unstructured":"Packer M. Pathophysiological mechanisms underlying the effects of \u0392-adrenergic agonists and antagonists on functional capacity and survival in chronic heart failure. Circulation 1990;82 Suppl 1:177\u201388.","journal-title":"Circulation"},{"key":"BF02178563_CR45","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/BF03029728","volume":"5","author":"H Persson","year":"1991","unstructured":"Persson H, Erhardt L. Beta receptor antagonists in the treatment of heart failure. Cardiovasc Drugs Ther 1991;5:589\u2013604.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"Suppl 1","key":"BF02178563_CR46","first-page":"112","volume":"82","author":"MR Bristow","year":"1990","unstructured":"Bristow MR, Hershberger RE, Port JD, Gilbert EM, Sandoval A, Rasmussen R, et al. \u0392-Adrenergic pathways in non-failing and failing human ventricular myocardium. Circulation 1990;82 Suppl 1:112\u201325.","journal-title":"Circulation"},{"key":"BF02178563_CR47","first-page":"203","volume":"43","author":"OE Brodde","year":"1991","unstructured":"Brodde OE. \u03921 and \u03922-Adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev 1991;43:203\u201342.","journal-title":"Pharmacol Rev"},{"issue":"Suppl 1","key":"BF02178563_CR48","first-page":"11","volume":"82","author":"M Packer","year":"1990","unstructured":"Packer M. Role of the sympathetic nervous system in chronic heart failure. Circulation 1990;82 Suppl 1:11\u20136.","journal-title":"Circulation"},{"key":"BF02178563_CR49","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/0002-9149(85)90396-0","volume":"55","author":"JL Anderson","year":"1985","unstructured":"Anderson JL, Lutz JR, Gilbert EM, Sorenson SG, Yanowitz FG, Menlove RL, et al. A randomized trial of low-dose \u0392-blockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 1985;55:471\u20135.","journal-title":"Am J Cardiol"},{"issue":"Suppl 4","key":"BF02178563_CR50","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2165\/00003495-199400474-00006","volume":"47","author":"A Hjalmarson","year":"1994","unstructured":"Hjalmarson A, Waagstein F. The role of \u0392-blockers in the treatment of cardiomyopathy and ischaemic heart failure. Drugs 1994;47 Suppl 4:31\u201340.","journal-title":"Drugs"},{"key":"BF02178563_CR51","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2165\/00003495-199142030-00002","volume":"42","author":"H Reicher-Reiss","year":"1991","unstructured":"Reicher-Reiss H, Barasch E. Calcium antagonists in patients with heart failure. Drugs 1991;42:343\u201364.","journal-title":"Drugs"},{"key":"BF02178563_CR52","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S0735-1097(86)80333-3","volume":"7","author":"MA Creager","year":"1986","unstructured":"Creager MA, Faxon DP, Cutler SS, Kohlmann O, Ryan TJ, Gavras H. Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison with the renin-angiotensin system and the sympathetic nervous system. J Am Coll Cardiol 1986;7:758\u201365.","journal-title":"J Am Coll Cardiol"},{"key":"BF02178563_CR53","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/0002-9149(85)90743-X","volume":"55","author":"P Nicod","year":"1985","unstructured":"Nicod P, Waeber B, Bussien JP, Goy JJ, Turini G, Nussberger J, et al. Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure. Am J Cardiol 1985;55:1043\u20137.","journal-title":"Am J Cardiol"},{"key":"BF02178563_CR54","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1161\/01.CIR.81.1.308","volume":"81","author":"RA Mulinari","year":"1990","unstructured":"Mulinari RA, Gavras I, Wang YX, Kohlmann O, Gavras H. Effects of a vasopressin antagonist with combined antipressor and antidiuretic activities in rats with left ventricular dysfunction. Circulation 1990;81:308\u201311.","journal-title":"Circulation"},{"key":"BF02178563_CR55","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJM198608283150901","volume":"315","author":"A Raine","year":"1986","unstructured":"Raine A, Erne P, Burgisser E. Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. N Engl J Med 1986;315:533\u20137.","journal-title":"N Engl J Med"},{"key":"BF02178563_CR56","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/0002-9149(92)91196-B","volume":"70","author":"D Eisner","year":"1992","unstructured":"Eisner D, M\u00fcntze A, Kromer EP, Riegger AJ. Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure. Am J Cardiol 1992, 70:494\u20138.","journal-title":"Am J Cardiol"},{"key":"BF02178563_CR57","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1161\/01.CIR.86.4.1089","volume":"86","author":"T M\u00fcnzel","year":"1992","unstructured":"M\u00fcnzel T, Kurz S, Holtz J, Busse R, Steinhauer H, Just H, Drexler H. Neurohormonal inhibition and hemodynamic unloading during prolonged inhibition of ANF degradation in patients with severe chronic heart failure. Circulation 1992;86:1089\u201398.","journal-title":"Circulation"}],"container-title":["Pharmacy World & Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02178563.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02178563\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02178563","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T12:32:03Z","timestamp":1557923523000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02178563"}},"subtitle":["Currently used and experimental drugs"],"short-title":[],"issued":{"date-parts":[[1994,12]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1994,12]]}},"alternative-id":["BF02178563"],"URL":"https:\/\/doi.org\/10.1007\/bf02178563","relation":{},"ISSN":["0928-1231","1573-739X"],"issn-type":[{"value":"0928-1231","type":"print"},{"value":"1573-739X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994,12]]}}}